Abstract CT182: Neoadjuvant immuno-radiotherapy (NIRT) in head and neck cancer: Phase I/Ib study of combined PD-1/SBRT prior to surgical resectionRom S. Leidner, Marka R. Crittenden, R. Bryan Bell et al.|Cancer Research|2019Cited by 4
Abstract CT112: An off-the-shelf multivalent vaccine containing cancer’s dark matter, DPV-001, combined with PD-1 +/- GITR in head & neck cancer: safety, efficacy, and immunodynamics from the phase 1 GITRVax trialRom S. Leidner, Bernard A. Fox, Quyen Vu et al.|Cancer Research|2024Cited by 3
The responses of HNSCC patients to immunotherapy are shown by two novel co-expression patternsNarmeen Daher-Ghanem, Nataly Kravchenko‐Balasha, Shay Sharon et al.|npj Precision Oncology|2025Cited by 2
Abstract CT182: Neoadjuvant immuno-radiotherapy (NIRT) in head and neck cancer: Phase I/Ib study of combined PD-1/SBRT prior to surgical resectionRom S. Leidner, Marka R. Crittenden, R. Bryan Bell et al.|Clinical Trials|2019Cited by 1
Abstract B01: Surgical outcomes following neoadjuvant hypofractionated radiation in combination with nivolumab: High rate of pathologic complete response in patients with p16+ head and neck squamous cell carcinomaR. Bryan Bell, Marka R. Crittenden, Rom S. Leidner et al.|Clinical Cancer Research|2020Cited by 1